Database Query Results : Magnolol, ,

MAG, Magnolol: Click to Expand ⟱
Features:
Lignan found in bark of some magnolia species.
Magnolol (MAG) — a bioactive biphenolic compound from Magnolia officinalis
derived from the bark (roots and branches) of Magnolia species such as M. officinalis, M. obovata, and M. grandiflora
The two main bioactive compounds isolated from these plants are MAG (5,5ʹ-diallyl-2,2ʹ-dihydroxybiphenyl) and Honokiol (3,5ʹ-diallyl-4,2ʹ-dihydroxybiphenyl) (Fig. 1) which are phenolic regioisomers.
In the bark extracts of Magnolia plants, the composition of MAG ranges from 1 to 10%, while Honokiol comprises 1 to 5%
major pathways and molecular targets involved in magnolol’s anticancer actions:
-Apoptosis: ↑ Bax, ↓ Bcl-2, ↑ cytochrome c, ↑ caspase-9, ↑ caspase-3
-Arrests cell cycle at G0/G1 or G2/M phase:↓ Cyclin D1, CDK4, CDK6, Cyclin B1, CDK1
-Inhibits NF-κB activation: ↓ IκBα, COX-2, TNF-α
-Inhibits PI3K, Akt, and mTOR phosphorylation
-Suppresses angiogenesis: ↓ Bcl-XL, Mcl-1, VEGF, cyclin D1
-Inhibits β-catenin nuclear translocation
-increase ROS production in tumor cells → triggers mitochondrial apoptosis
-Magnolol activates Nrf2 in normal cells → upregulates HO-1, NQO1: Protects normal tissue from oxidative stress during chemotherapy or inflammation.



Scientific Papers found: Click to Expand⟱
4522- HNK,  MAG,    Honokiol Is More Potent than Magnolol in Reducing Head and Neck Cancer Cell Growth
- in-vitro, HNSCC, FaDu
AntiCan↑, tumCV↓, eff↑, survivin↓, RadioS↑,
4523- HNK,  MAG,  BA,    Honokiol-Magnolol-Baicalin Possesses Synergistic Anticancer Potential and Enhances the Efficacy of Anti-PD-1 Immunotherapy in Colorectal Cancer by Triggering GSDME-Dependent Pyroptosis
- in-vitro, CRC, HCT116 - in-vitro, CRC, LoVo - in-vivo, CRC, HCT116
AntiCan↑, eff↑, TumCP↓, TumCCA↓, cycD1/CCND1↓, Pyro↑, Apoptosis↑, cl‑GSDME↑, Bcl-2↓, Cyt‑c↑, Casp9↑, TumCG↓,
4537- MAG,    Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action
- in-vivo, Melanoma, NA - in-vitro, Melanoma, A431
*cl‑Casp8↑, *PARP↑, *P21↑, tumCV↓, TumCP↓, TumCCA↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK4↓, CDC2↓, P21↑, Apoptosis↑,
972- MAG,    Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells
- vitro+vivo, Bladder, T24
angioG↓, VEGF↓, H2O2↓, Hif1a↓, VEGFR2↓, Akt↓, mTOR↓, P70S6K↓, 4E-BP1↓, TumCG↓, CD31↓, CA↓,
4536- MAG,    Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis
- in-vitro, Liver, HepG2 - in-vivo, CRC, COLO205
AntiCan↑, selectivity↑, TumCCA↑, P21↑, Apoptosis↑,
4535- MAG,  5-FU,    Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways
- in-vitro, Cerv, NA
ChemoSen↑, TumCP↓, vinculin↓, TumCA↓, TumCMig↓, TumCI↓, p‑Akt↓, p‑PI3K↓, mTOR↓, E-cadherin↑, β-catenin/ZEB1↑, Snail↓, Slug↓,
4534- MAG,    Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells
- in-vitro, Liver, HepG2 - in-vitro, CRC, COLO205
AntiCan↑, Apoptosis↑, selectivity↑, Ca+2↑, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓,
4533- MAG,    Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways
- in-vitro, GC, SGC-7901
AntiCan↑, DNAdam↑, Apoptosis↑, TumCCA↑, Bax:Bcl2↑, MMP↓, Casp3↑, PI3K↓, Akt↓,
4532- MAG,  Cisplatin,    Magnolol Attenuates Cisplatin-Induced Muscle Wasting by M2c Macrophage Activation
- in-vivo, Var, NA
cachexia↓, *IGF-1↑, chemoP↑, *M2 MC↑,
4531- MAG,    Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway
- in-vitro, CRC, HCT116
Apoptosis↑, DNAdam↑, Casp3↑, cl‑PARP↑, p‑AMPK↑, Bcl-2↓, P53↑, BAX↑, Cyt‑c↑, TumCMig↓, TumCI↓,
4530- MAG,    Magnolol inhibits cancer stemness and IL-6/Stat3 signaling in oral carcinomas
- in-vitro, Oral, NA
CSCs↓, ChemoSen↑,
4529- MAG,    Effectiveness of Magnolol, a Lignan from Magnolia Bark, in Diabetes, Its Complications and Comorbidities—A Review
- Review, Diabetic, NA
*AntiDiabetic↑, *glucose↓, *SOD↑, *Catalase↑, *ROS↓, *MDA↓, *GPx↑, *CYP2E1↓, *AGEs↓, *IL10↑, *neuroP↑, *GutMicro↑,
4528- MAG,    Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update
- Review, Nor, NA
*Inflam↑, *cardioP↑, *angioG↓, *antiOx↑, *neuroP↑, *Bacteria↓, AntiTum↑, TumCG↓, TumCMig↓, TumCI↓, Apoptosis↑, E-cadherin↑, NF-kB↓, TumCCA↑, cycD1/CCND1↓, PCNA↓, Ki-67↓, MMP2↓, MMP7↓, MMP9↓, TumCG↓, Casp3↑, NF-kB↓, Akt↓, mTOR↓, LDH↓, Ca+2↑, eff↑, *toxicity↓, *BioAv↝, *PGE2↓, *TLR2↓, *TLR4↓, *MAPK↓, *PPARγ↓,
4527- MAG,    Magnolol inhibits growth and induces apoptosis in esophagus cancer KYSE-150 cell lines via the MAP kinase pathway
- in-vitro, ESCC, TE1 - in-vitro, ESCC, Eca109 - vitro+vivo, SCC, KYSE150
TumCP↓, TumCMig↓, MMP2↓, Apoptosis↑, cl‑Casp3↑, cl‑Casp9↑, BAX↑, Bcl-2↓, p‑p38↓, TumCG↓,
4526- MAG,  HNK,    Targeting apoptosis pathways in cancer with magnolol and honokiol, bioactive constituents of the bark of Magnolia officinalis
- Review, Var, NA
*antiOx↑, *Inflam↓, *Bacteria↓, *toxicity↓, AntiTum↑, Apoptosis↑, DR5↝,
4525- MAG,  HNK,    Magnolol and Honokiol: Two Natural Compounds with Similar Chemical Structure but Different Physicochemical and Stability Properties
- Study, Nor, NA
*BioAv↝, *eff↑,
4524- MAG,    Magnolol facilitates mitochondrial-peroxisome dysfunction and induces oxeiptosis in lung cancer cells following transfer via tunneling nanotubes
- vitro+vivo, Lung, NA
ROS↑, antiOx↓, mtDam↑,
4521- MAG,  HNK,    Safety and Toxicology of Magnolol and Honokiol
- Review, Nor, NA
*antiOx↑, *Inflam↓, *Bacteria↓, *toxicity↓,
4520- MAG,    Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
- vitro+vivo, PC, PANC1
Vim↓, E-cadherin↑, EMT↓, N-cadherin↓, p‑SMAD2↓, p‑SMAD3↓, TumCP↓, TumCMig↓, TumCI↓, TGF-β↓,
4519- MAG,    Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer
- Review, Var, NA
*antiOx↑, *Inflam↓, *Bacteria↓, *AntiAg↑, *BBB↑, *BioAv↓, BAD↑, Casp3↑, Casp6↑, Casp9↑, JNK↑, Bcl-xL↓, PTEN↑, Akt↓, NF-kB↓, MMP7↓, MMP9↓, uPA↓, Hif1a↓, VEGF↓, FOXO3↓, Ca+2↑, TumCCA↑, ROS↑, Cyt‑c↑,
4518- MAG,  Cisplatin,    Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells
- in-vitro, GC, MKN45
ChemoSen↑, tumCV↓, BAX↑, Bcl-2↓, P21↑, P53↑, MMP9↓,
4517- MAG,    Mitochondrion-targeted magnolol derivatives exert synergistic anticancer activity by modulating energy metabolism and tumor microenvironment
- vitro+vivo, Var, NA
eff↑, AntiCan↑, ROS↑, ER Stress↑, Apoptosis↑,
4516- MAG,    Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models
- in-vivo, NSCLC, NA
selectivity↑, Apoptosis↑, TumCCA↑, Casp3↑, cycD1/CCND1↓, CDK4↓, VEGF↓, FOXP3↓, IDO1↓,
4515- MAG,    Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight
- Review, Var, NA
AntiCan↑, TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↑, angioG↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, NF-kB↓,
4514- MAG,    Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential
- Review, Var, NA
AntiCan↑, TumCP↓, TumCCA↑, TumMeta↓, angioG↓, NF-kB↓, MAPK↓, PI3K↓, Akt↓, mTOR↓, BioAv↓, *antiOx↑, *Inflam↓, *AntiAg↑, ChemoSen↑, cycD1/CCND1↓, CycB/CCNB1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p27↑, P21↑, P53↑, PTEN↓, XIAP↓, Mcl-1↓, Casp3↑, Casp9↑, MMP9↑,
1314- MAG,    Magnolol induces apoptosis via activation of both mitochondrial and death receptor pathways in A375-S2 cells
- in-vitro, Melanoma, A375
TumCP↓, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓, BAX↑,
1198- MAG,    Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells
- in-vivo, Melanoma, NA
OXPHOS↓, TumCP↓,
1197- MAG,    Magnolol as STAT3 inhibitor for treating multiple sclerosis by restricting Th17 cells
- in-vivo, MS, NA
Weight↑, Th17↓, STAT3↓,
1196- MAG,    2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression
- in-vitro, HCC, NA
TumCG↓, TumCMig↓, TumCI↓, TumCCA↑, HDAC↓,
1089- MAG,    Magnolol potently suppressed lipopolysaccharide-induced iNOS and COX-2 expression via downregulating MAPK and NF-κB signaling pathways
- in-vitro, AML, RAW264.7
p‑IκB↓, NF-kB↓, p‑ERK↓, p‑JNK↓, p‑PI3K↓, p‑Akt↓, iNOS↓, COX2↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 30

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

antiOx↓, 1,   H2O2↓, 1,   OXPHOS↓, 1,   ROS↑, 3,  

Mitochondria & Bioenergetics

CDC2↓, 1,   MMP↓, 1,   mtDam↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis

p‑AMPK↑, 1,   IDO1↓, 1,   LDH↓, 1,  

Cell Death

Akt↓, 6,   p‑Akt↓, 2,   Apoptosis↑, 12,   BAD↑, 1,   BAX↑, 4,   Bax:Bcl2↑, 1,   Bcl-2↓, 6,   Bcl-xL↓, 1,   Casp3↑, 8,   cl‑Casp3↑, 1,   Casp6↑, 1,   Casp8↑, 2,   Casp9↑, 5,   cl‑Casp9↑, 1,   Cyt‑c↑, 4,   DR5↝, 1,   cl‑GSDME↑, 1,   iNOS↓, 1,   JNK↑, 1,   p‑JNK↓, 1,   MAPK↓, 2,   Mcl-1↓, 1,   p27↑, 1,   p‑p38↓, 1,   Pyro↑, 1,   survivin↓, 1,  

Transcription & Epigenetics

tumCV↓, 3,  

Protein Folding & ER Stress

ER Stress↑, 1,  

DNA Damage & Repair

DNAdam↑, 2,   P53↑, 3,   cl‑PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence

CDK2↓, 1,   CDK4↓, 3,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 1,   P21↑, 4,   TumCCA↓, 1,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State

4E-BP1↓, 1,   CSCs↓, 1,   EMT↓, 1,   p‑ERK↓, 1,   FOXO3↓, 1,   HDAC↓, 1,   mTOR↓, 5,   P70S6K↓, 1,   PI3K↓, 3,   p‑PI3K↓, 2,   PTEN↓, 1,   PTEN↑, 1,   STAT3↓, 1,   TumCG↓, 6,  

Migration

CA↓, 1,   Ca+2↑, 3,   CD31↓, 1,   E-cadherin↑, 3,   Ki-67↓, 1,   MMP2↓, 2,   MMP7↓, 2,   MMP9↓, 3,   MMP9↑, 1,   N-cadherin↓, 1,   Slug↓, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TumCA↓, 1,   TumCI↓, 5,   TumCMig↓, 6,   TumCMig↑, 1,   TumCP↓, 9,   TumMeta↓, 1,   uPA↓, 1,   Vim↓, 1,   vinculin↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature

angioG↓, 3,   Hif1a↓, 2,   VEGF↓, 3,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling

COX2↓, 1,   FOXP3↓, 1,   p‑IκB↓, 1,   NF-kB↓, 6,   Th17↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 1,   ChemoSen↑, 4,   eff↑, 4,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers

Ki-67↓, 1,   LDH↓, 1,  

Functional Outcomes

AntiCan↑, 8,   AntiTum↑, 2,   cachexia↓, 1,   chemoP↑, 1,   Weight↑, 1,  
Total Targets: 112

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 5,   Catalase↑, 1,   CYP2E1↓, 1,   GPx↑, 1,   MDA↓, 1,   ROS↓, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis

glucose↓, 1,   PPARγ↓, 1,  

Cell Death

cl‑Casp8↑, 1,   MAPK↓, 1,  

DNA Damage & Repair

PARP↑, 1,  

Cell Cycle & Senescence

P21↑, 1,  

Proliferation, Differentiation & Cell State

IGF-1↑, 1,  

Migration

AntiAg↑, 2,  

Angiogenesis & Vasculature

angioG↓, 1,  

Barriers & Transport

BBB↑, 1,  

Immune & Inflammatory Signaling

IL10↑, 1,   Inflam↓, 4,   Inflam↑, 1,   M2 MC↑, 1,   PGE2↓, 1,   TLR2↓, 1,   TLR4↓, 1,  

Protein Aggregation

AGEs↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 1,   BioAv↝, 2,   eff↑, 1,  

Clinical Biomarkers

GutMicro↑, 1,  

Functional Outcomes

AntiDiabetic↑, 1,   cardioP↑, 1,   neuroP↑, 2,   toxicity↓, 3,  

Infection & Microbiome

Bacteria↓, 4,  
Total Targets: 34

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:121  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page